9 not yet recruiting, 5 completed, 5 recruiting, 1 terminated. 22 Phase 2, 8 Phase 1, 2 Phase 3.
Follow Multiple Myeloma (MM): new trials by email Literature Review of Multiple Myeloma (MM) trials Research Report on Multiple Myeloma (MM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Zealand University Hospital | 150 | 2027-03-01 | 2026-09-25 |
| MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | University of Arkansas | 50 | 2027-03-01 | 2026-09-02 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease QLS4131 - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 55 | 2026-12-01 | 2026-10-29 |
| F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma F182112 Plus Isatuximab and Lenalidomide - Multiple Myeloma (MM), Transplant-eligible Patients | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-10-01 | 2026-09-18 |
| Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma anti-BCMA/CD3 bispecific antibody - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 15 | 2026-10-01 | 2026-08-27 |
| CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment CM336 Plus Isatuximab - Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 26 | 2026-09-10 | 2026-09-17 |
| HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease HP-001, Dexamethasone - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-09-01 | 2026-09-10 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 46 | 2026-09-01 | 2026-09-04 |
| Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification Sonrotoclax, CM336 (BCMA/CD3 bispecific antibody) - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2026-08-01 | 2026-07-07 |
| A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Linvoseltamab, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Withdrawn | Regeneron Pharmaceuticals | 2026-06-05 | 2026-06-18 | |
| Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. Teclistamab, Talquetamab, Daratumumab - Multiple Myeloma (MM) | Phase 2 | Recruiting | European Myeloma Network B.V. | 150 | 2025-12-12 | 2026-04-15 |
| A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies BT02 - Relapsed or Refractory Hematologic Malignancies, Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Biotroy Therapeutics | 116 | 2025-10-01 | 2025-09-17 |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM) | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 100 | 2025-08-08 | 2026-06-04 |
| A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies IDP-121 - Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Recruiting | IDP Discovery Pharma S.L. | 37 | 2023-06-05 | 2025-05-01 |
| Phase I Trial of GR1803 Injection in Patients With RRMM GR1803 injection - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Completed | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 76 | 2022-05-27 | 2025-08-05 |
| Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma OPC-415 - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Terminated | Otsuka Pharmaceutical Co., Ltd. | 11 | 2021-02-18 | 2026-09-14 |
| A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications NKR-2 cells - Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM) | Phase 1 / Phase 2 | Unknown | Celyad Oncology SA | 146 | 2016-12-01 | 2019-09-19 |
| Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. Carfilzomib, Cyclophosphamide, Lenalidomide - MULTIPLE MYELOMA (MM) | Phase 2 | Completed | Mario Boccadoro | 477 | 2015-02-01 | 2026-04-14 |
| Study Evaluating Venetoclax in Subjects With Hematological Malignancies azacitadine, venetoclax, rituximab / IDEC-C2B8 - Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) | Phase 1 / Phase 2 | Completed | AbbVie | 38 | 2014-09-22 | 2021-08-02 |
Showing 20 of 22. Sign in to see all of them.
Multiple Myeloma (22) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Non-Hodgkin (2) · Recurrence (2) · Febrile Neutropenia (1) · GATA2 Deficiency (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoproliferative Disorders (1)
Blood Protein Disorders (22) · Cardiovascular Diseases (22) · Hematologic Diseases (22) · Hemic and Lymphatic Diseases (22) · Hemorrhagic Disorders (22) · Hemostatic Disorders (22) · Immune System Diseases (22) · Immunoproliferative Disorders (22) · Neoplasms (22) · Neoplasms by Histologic Type (22) · Neoplasms, Plasma Cell (22) · Paraproteinemias (22) · Vascular Diseases (22) · Lymphoproliferative Disorders (21) · Disease Attributes (5)
Lenalidomide (6) · Dexamethasone (5) · daratumumab (5) · Bortezomib (3) · Melphalan (2) · isatuximab (2) · talquetamab (2) · Calcium Dobesilate (1) · Ceftazidime (1) · Ciprofloxacin (1) · Cyclophosphamide (1) · Leukapheresis (1) · Magnetic Resonance Spectroscopy (1) · Maintenance (1) · Rituximab (1)
Institute of Hematology & Blood Diseases Hospital, China (6) · SCRI Development Innovations, LLC (2) · AbbVie (1) · Alliance for Clinical Trials in Oncology (1) · Biotroy Therapeutics (1) · Celyad Oncology SA (1) · European Myeloma Network B.V. (1) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1) · IDP Discovery Pharma S.L. (1) · Mario Boccadoro (1) · Memorial Sloan Kettering Cancer Center (1) · Otsuka Pharmaceutical Co., Ltd. (1) · Polyphor Ltd. (1) · Regeneron Pharmaceuticals (1) · University of Arkansas (1)
United States (6) · China (5) · Italy (2) · Japan (2) · Spain (2) · Belgium (1) · Denmark (1) · Netherlands (1) · Norway (1)
Alessandra Larocca (1) · Antonio Palumbo, MD (1) · Daniel Couriel, M.D. (1) · Enrique Ocio San Miguel, MD, PhD (1) · Fredrik Schjesvold (1) · Hani Hassoun, MD (1) · Hans Lee, MD (1) · Henning Schade, MD (1) · Hira Shaikh, MBBS (1) · Jie Jin, PhD (1) · Maria-Victoria Mateos (1) · Niels van de Donk (1)
PMID 29133316, PMID 34774221, PMID 35666982, PMID 36528035, PMID 36764323, PMID 38048557, PMID 38849344
2025 (1)